EBITDA Margin % is calculated as EBITDA divided by its Revenue. Stenocare AS's EBITDA for the
three
months ended in Mar. 2026 was kr0.06 Mil. Stenocare AS's Revenue for the
three
months ended in Mar. 2026 was kr3.00 Mil. Therefore, Stenocare AS's EBITDA margin for the quarter that ended in Mar. 2026 was 2.03%.
Stenocare AS (OCSE:STENO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Stenocare AS EBITDA Margin % Related Terms
Stenocare AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Stenocare AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:STENO vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Stenocare AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stenocare AS (OCSE:STENO) has a EBITDA Margin % of 2.03% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stenocare AS and its competitors. According to the industry distribution chart, Stenocare AS ranks #699 out of 956 companies in the Drug Manufacturers industry, placing it in the top 73.1%.
Is Stenocare AS's EBITDA Margin % too high?
Stenocare AS's current EBITDA Margin % is 2.03%. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Stenocare AS's value of 2.03% is 83.8% below this industry median. Based on the distribution chart, Stenocare AS ranks #699 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Stenocare AS has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #699 out of 956 companies for EBITDA Margin %. This places Stenocare AS in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Stenocare AS's value of 2.03% is 83.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stenocare AS's current EBITDA Margin % of 2.03% is 83.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stenocare AS and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stenocare AS's current EBITDA Margin % is 2.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (OCSE:STENO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.31, compared to a current price of kr1.00 — trading 56.7% below its estimated fair value. The current EBITDA Margin % is 2.03% and 83.8% below the Drug Manufacturers industry median of 12.52. Stenocare AS's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Stenocare AS (OCSE:STENO), the current EBITDA Margin % is 2.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (OCSE:STENO) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of kr1.00 is trading 56.7% below its estimated GF Value™ of kr2.31.
GuruFocus considers Stenocare AS to be Possible Value Trap.
Key valuation signals for OCSE:STENO:
EBITDA Margin %: 2.03%
GF Value™: kr2.31 vs. price of kr1.00 (56.7% below fair value)
Industry Position: 83.8% below the Drug Manufacturers median (#699 of 956)
No single metric tells the full story. See the OCSE:STENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
49GF Score
Get the complete analysis for OCSE:STENO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:STENO has been successfully added to your 
